Sarén, Tina http://orcid.org/0000-0001-5227-6779
Saronio, Giulia
Marti Torrell, Paula
Zhu, Xu
Thelander, Josefin
Andersson, Yasmin
Hofström, Camilla
Nestor, Marika
Dimberg, Anna http://orcid.org/0000-0003-4422-9125
Persson, Helena
Ramachandran, Mohanraj http://orcid.org/0000-0003-2685-0575
Yu, Di http://orcid.org/0000-0002-8636-0351
Essand, Magnus http://orcid.org/0000-0002-9725-0422
Funding for this research was provided by:
Vetenskapsrådet (2019-01326)
Cancerfonden (19 0184Pj)
Barncancerfonden (PR2020-0167, TJ 2019-0014)
The Sjöberg Foundation
Article History
Received: 20 December 2021
Accepted: 19 July 2023
First Online: 10 August 2023
Competing interests
: D.Y. and M.E. are co-founders of Elicera Therapeutics, which has submitted a patent application on the described IL13Ra2-directed scFv sequences. M.N. is co-founder of Akiram Therapeutics, which has submitted a patent application on CD44v6-targeted antibodies. The remaining authors declare no competing interests.